<DOC>
	<DOCNO>NCT01842451</DOCNO>
	<brief_summary>A Phase 2 Study Evaluate Safety , Efficacy , Pharmacokinetics , Pharmacodynamics VX-135 Daclatasvir Treatment-Naïve Adult Subjects With Genotype 1 Chronic Hepatitis C</brief_summary>
	<brief_title>A Phase 2 Study Evaluate Safety , Efficacy , Pharmacokinetics , Pharmacodynamics VX-135 Daclatasvir Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Subjects must genotype 1 CHC evidence HCV infection least 6 month screen Subjects must treatmentnaïve received prior treatment interferon , immunomodulatory agent , DAA HCV Evidence cirrhosis History clinical evidence significant unstable cardiac disease Any cause significant liver disease addition hepatitis C Creatinine clearance ≤50 mL/min use CockcroftGault equation screen Female subject pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>